T. Rowe Price Investment Management, Inc. 13D and 13G filings for Cytokinetics, Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:18 pm Purchase | 2025-09-30 | 13G | Cytokinetics, Incorporated CYTK | T. Rowe Price Investment Management, Inc. | 19,097,373 16.000% | 1,494,933 (+8.49%) | Filing |
| 2025-08-14 12:12 pm Purchase | 2025-06-30 | 13G | Cytokinetics, Incorporated CYTK | T. Rowe Price Investment Management, Inc. | 17,602,440 14.700% | 4,182,296 (+31.16%) | Filing |
| 2025-05-07 10:37 am Purchase | 2025-04-30 | 13G | Cytokinetics, Incorporated CYTK | T. Rowe Price Investment Management, Inc. | 13,420,144 11.300% | 3,730,157 (+38.49%) | Filing |
| 2024-11-14 1:28 pm Purchase | 2024-09-30 | 13G | Cytokinetics, Incorporated CYTK | T. Rowe Price Investment Management, Inc. | 9,689,987 8.200% | 9,689,987 (New Position) | Filing |